Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.

Sci Rep · 2020 · PMC7471311 · PMID 32884119

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Previous US data showed a trend towards higher time to discontinuation of anti-PD-1 agents (pembrolizumab or nivolumab monotherapies) compared to combination therapy 7 , 9 .

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The comparisons between initiators of nivolumab/ipilimumab versus nivolumab monotherapy did not reach statistical significance (Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.